Urinary neopterin in patients with diabetes mellitus and foot ulcers

Pteridines

Volumn 18, Issue 4, 2007, Pages 128-131

  Melicharova, Karolina ^a   Kusalova, Marie ^a   Smahelova, Alena ^a   Hyspler, Radomir ^a   Solichova, Dagmar ^a   Melichar, Bohuslav ^a,b  

^a UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Diabetes mellitus; Diabetic foot; Glycosylated hemoglobin; Neopterin

Indexed keywords

INSULIN; NEOPTERIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEUROPATHY; FEMALE; FOOT ULCER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANK SUM TEST; URINALYSIS;

EID: 39049170980     PISSN: 09334807     EISSN: 21954720     Source Type: Journal    
DOI: 10.1515/pteridines.2007.18.1.128     Document Type: Article

References (17)

1. Wachter H, Fuchs D, Hausen A, Reibnegger G, Werner ER. Neopterin as marker for activation of cellular immunity: immunologic basis and clinical application. Adv Clin Chem 1989; 27: 81-141.
2. Manna R, Gambassi G, Papa G, et al. Urinary neopterin levels of insulin dependent diabetes (IDDM) at onset: In: Pfleiderer W, Wachter H, Blair JA, eds. Biochemical and Clinical Aspects of Pteridines. Walter de Gruyter: Berlin, 1987: 353-357.
3. Manna R, Salvatore M, Di Leo MAS, et al. Relationship between urinary neopterin excretion and islet cell antibodies in type 1 (insulin-dependent) diabetes. Diabetes Res 1991; 17: 33-36.
4. Jeffcoate WJ, Macfarlane RM, Fletcher EM. The description and classification of diabetic foot lesions. Diabet Med 1993; 10: 676-679.
5. Cermanova M, Melichar B, Solichova D, et al. Urinary neopterin and microalbuminuria in patients treated by low-density lipoprotein apheresis. Pteridines 2005; 16: 174-183.
6. Hoelzel W, Weykamp C, Jeppesson JO, et al. IFCC reference system for measurement of hemoglobin A, in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study. Clin Chem 2004; 50: 166-174.
7. Weitgasser R, Lechleitner M, Koch T, et al. Antibodies to heat shock protein 65 and neopterin levels in patients with type 1 diabetes mellitus. Exp Clin Endocrinol Diabetes 2003; 111: 127-131.
8. Bertz L, Barani J, Gottsater A, Nilsson PM, Mattiasson I, Lindblad B. Are there differences of inflammatory bio-markers between diabetic and non-diabetic patients with critical limb ischemia? Int Angiol 2006; 25: 370-377.
9. Bodlaj G, Berg J, Pichler R, Sailer T, Biesenbach G. Type 2 diabetes in patients with end-stage renal disease is not associated with further increased serum inflammatory parameters. J Nephrol 2004; 17: 112-117.
10. Weiss MF, Rodby RA, Justice AC, Hricik DE. Free pentosidine and neopterin as markers of progression rate in diabetic nephropathy. Kidney Int 1998; 54: 193-202.
11. Gottsater A, Rendell M, Anwaar I, Lindgarde F, Hulthen UL, Mattiasson I. Increasing neopterin and decreasing endothelin-1 in plasma during insulin infusion in women. Scand J Clin Lab Invest 1999; 59: 417-424.
12. Tatzber F, Rabl H, Koriska K, et al. Elevated serum neopterin levels in atherosclerosis. Atherosclerosis 1991; 89: 203-208.
13. Weiss G, Willeit J, Kiechl S, et al. Increased concentrations of neopterin in carotid atherosclerosis. Atherosclerosis 1994; 106: 263-271.
14. Rudzite V, Jurika E, Erglis A, Trusinskis K, Jegere S, Fuchs D. Intravascular ultrasound data and results of serum biochemical indices at the time of stenting and after six months in patients with coronary artery disease. Pteridines 2006; 17: 95-99.
15. Avanzas P, Arroyo-Espliguero R, Quiles J, Roy D, Kaski JC. Elevated serum neopterin predicts future adverse cardiac events in patients with chronic stable angina pectoris. Eur Heart J 2005; 26: 457-463.
16. Ray KK, Morrow DA, Sabatine MS, Shui A, Rifai N, Cannon CP, Braunwald E. Long-term prognostic value of neopterin: a novel marker of monocyte activation in patients with acute coronary syndrome. Circulation 2007; 115: 3071-3078.
17. Schroecksnadel K, Frick B, Winkler C, Fuchs D. Crucial role of interferon-gamma and stimulated macrophages in cardiovascular disease. Current Vasc Pharmacol 2006; 4: 205-213.